OncoMatch/Clinical Trials/NCT05299424
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Is NCT05299424 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for multiple myeloma.
Treatment: CM336_group 8a · CM336_group 8b · CM336_group 1 · CM336_group 9 · CM336_group 2a · CM336_group 2b · CM336_group 3a · CM336_group 3b · CM336_group 4a · CM336_group 4b · CM336_group 5 · CM336_group 6a · CM336_group 6b · CM336_group 7 · CM336_RP2D — This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma. This study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ). The safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of CM336 will be evaluated in Phase 2 study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 monoclonal antibody
Cannot have received: bcma-targeted therapy
Cannot have received: car-t cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05299424 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bcma-targeted therapy, car-t cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages